NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (128)	1/14/1999 2:39:00 PM
From: Steve Lokness	Read Replies (1) of 613

TexasDude; The money crunch with the biotechs is real and one of the things I looked at when making my choices. It is also a good reason to look at ABSC. I do not believe that ABSC has anything in trials now or is expected to soon. I believe that ABSC is trying to get themselves in a position that they do not have to depend on drug development for ongoing operations, but rather have the revenue coming from the sale of their systems for this. They will sell several of their machines to drug developers and of course have their own. The libraries of compounds probably depends on the agreement with their customers and I would think differs, maybe depending on prioritized targets. Again from Vector1 who seems to have seen the presentation by ABSC; Message 7276270 Good Investing; Steve

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next